Your Health, We Care
Another Name飞尼妥，LuciEver，Afinitor
IndicationsIndicated for the treatment of advanced hormone receptor-positive, HER2-negative breast cancer; neuroendocrine tumors of pancreatic, gastrointestinal, and pulmonary origin; advanced renal cell carcino
Reg No.02 L 1303/25
Inspection NO.425-25
Everolimus produced by Lucius Pharmaceuticals is a multi-targeted kinase inhibitor with well-established clinical efficacy and favorable tolerability, demonstrating significant therapeutic value in the treatment of various solid tumors and rare disease-related lesions.
Overview of Key Information for Everolimus.
The main active ingredient is everolimus.
Indicated for adult and pediatric patients with various cancers and tuberous sclerosis complex (TSC)-associated lesions.
The recommended general dosage is 10 mg orally once daily. The specific dosage should be adjusted based on the indication, body surface area, and blood concentration.
Dosage adjustment is required for patients with hepatic impairment.
Men and women of reproductive potential should use effective contraceptive measures during treatment.
In case of overdosage, seek medical attention immediately and initiate symptomatic and supportive treatment.
Store the drug in its original packaging at 20–25°C, protected from moisture and light.
Everolimus is metabolized by CYP3A4. Its blood concentration is affected by food and concurrent medications, requiring blood concentration monitoring.
FDA，2022.02
